Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

NCT05670951 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Intestinal Malabsorption

Interventions

DRUG: ELGN-2112
DRUG: Placebo

Sponsor

Elgan Pharma Ltd.